الدكتورة حنين ذويب، تشارك في نشر دراسة جديدة بعنوان “هل يُعدّ مستقبل β3-Adrenoceptor هدفًا صالحًا لعلاج السمنة و/أو مرض السكري من النوع الثاني؟”

الدكتورة حنين ذويب، تشارك في نشر دراسة جديدة بعنوان “هل يُعدّ مستقبل β3-Adrenoceptor هدفًا صالحًا لعلاج السمنة و/أو مرض السكري من النوع الثاني؟”

ملخص البحث

β3-Adrenoceptors mediate several functions in rodents that could be beneficial for the treatment of obesity and type 2 diabetes. This includes promotion of insulin release from the pancreas, cellular glucose uptake, lipolysis, and thermogenesis in brown adipose tissue. In combination, they lead to a reduction of body weight in several rodent models including ob/ob mice and Zucker diabetic fatty rats. These findings stimulated drug development programs in various pharmaceutical companies, and at least nine β3-adrenoceptor agonists have been tested in clinical trials. However, all of these projects were discontinued due to the lack of clinically relevant changes in body weight. Following a concise historical account of discoveries leading to such drug development programs we discuss species differences that explain why β3-adrenoceptors are not a meaningful drug target for the treatment of obesity and type 2 diabetes in humans.

 

كيفية الاستشهاد للبحث:

Dwaib, H. S., & Michel, M. C. (2023). Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes?. Biomolecules13(12), 1714.‏

 

رابط البحث

https://www.mdpi.com/2218-273X/13/12/1714